Today's Research Daily features a real-time update on the Q4 earnings season and fresh Chevron (CVX), Merck (MRK), QUALCOMM ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

Merck & Co., Inc. operates as a healthcare company worldwide. Based in Rahway, United States the company has 70,000 full time ...

Shares of Merck & Co. Inc. MRK shed 2.76% to $97.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Truist has recently reduced Merck & Co Inc (MRK) stock to Hold rating, as announced on January 8, 2025, according to Finviz. Earlier, on December 20, 2024, BMO Capital Markets had reduced the stock ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Guggenheim analyst Vamil Divan lowered the firm’s price target on Merck (MRK) to $122 from $130 and keeps a Buy rating on the shares. The firm ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage trial, causing its shares to hit a record ...